收费全文 | 1553篇 |
免费 | 118篇 |
国内免费 | 10篇 |
耳鼻咽喉 | 21篇 |
儿科学 | 38篇 |
妇产科学 | 13篇 |
基础医学 | 128篇 |
口腔科学 | 60篇 |
临床医学 | 131篇 |
内科学 | 447篇 |
皮肤病学 | 28篇 |
神经病学 | 99篇 |
特种医学 | 56篇 |
外科学 | 271篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 48篇 |
眼科学 | 65篇 |
药学 | 118篇 |
中国医学 | 4篇 |
肿瘤学 | 129篇 |
2023年 | 36篇 |
2022年 | 40篇 |
2021年 | 123篇 |
2020年 | 79篇 |
2019年 | 110篇 |
2018年 | 132篇 |
2017年 | 91篇 |
2016年 | 95篇 |
2015年 | 93篇 |
2014年 | 128篇 |
2013年 | 143篇 |
2012年 | 175篇 |
2011年 | 130篇 |
2010年 | 69篇 |
2009年 | 48篇 |
2008年 | 75篇 |
2007年 | 39篇 |
2006年 | 17篇 |
2005年 | 16篇 |
2004年 | 9篇 |
2003年 | 4篇 |
2002年 | 6篇 |
2001年 | 2篇 |
1998年 | 1篇 |
1990年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1982年 | 1篇 |
1979年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1967年 | 2篇 |
1965年 | 1篇 |
Introduction
Pin site infection is the commonest complication of Ilizarov external fixation. The aim of the study was to examine if use of antiseptics was superior over control and further if daily dressing was superior to weekly dressing in regular pin site care in reducing the burden of pin site infection in Ilizarov fixators.Patients and methods
A total of 114 patients (2363 pin sites) were randomised to receive regular pin site care alone (30 patients, 638 pin sites) or with additional application of povidone iodine (27 patients, 561 pin sites), silver sulfadiazine (27 patients, 570 pin sites) and chlorhexidine (30 patients, 594 pin sites). The pin tracts were sub-randomised to receive daily (1212 pin sites) or weekly (1151 pin sites) dressings. The primary outcome was pin site infection days rate across all four groups. The secondary outcomes were - mean duration to first episode of infection, differences between daily and weekly dressing groups, mean duration of antibiotic therapy and incidence of re-interventions and sequelae. We also recorded frequency of bacterial pathogens in all microbiological samples submitted. Block randomization using computer-generated random numbers was used. The assessor of outcome was blinded.Results
All patients completed the study. Pin site infection rate days per 1000 pin site days observed was marginally less in chlorhexidine group, but was not statistically significant compared to other antiseptics and control group (Absolute value in control, povidone iodine, silver sulphadiazine and chlorhexidine groups were respectively 2.04?±?4.27, 2.04?±?3.65, 1.85?±?3.37, 1.37?±?2.35, p value 0.92). Daily dressing category showed slightly less pin site infection days rate within each group and overall, but this was also not statistically significant (1.56?±?3.99 versus 2.10?±?5.1, p value 0.35). There was no statistically significant difference among the groups with regard to other secondary outcomes. Methicillin Sensitive Staphylococcus aureus was the most common bacterial pathogen isolated.Conclusion
Use of antiseptics does not offer any advantage in regular pin site care in Ilizarov external fixation and daily pin site care is not superior to weekly pin site care. Empirical therapy in early and low grade pin site infections must be targeted against Staphylococcus. 相似文献Methods: A systematic literature search was performed to identify relevant randomized controlled trials (RCTs). Key outcomes of interest were clinical response (CD activity index [CDAI] reduction of 100 points; CDAI-100) and remission (CDAI score under 150 points; CDAI < 150). A treatment sequence Bayesian NMA was conducted to account for the re-randomization of patients based on different clinical definitions, the lack of similarity of the common comparator for each trial and the full treatment pathway from the induction phase onwards.
Results: Thirteen RCTs were identified. Ustekinumab 90?mg q8w was associated with statistically significant improvement in clinical response relative to placebo and vedolizumab 300?mg. For clinical remission, ustekinumab 90?mg q8w was associated with statistically significant improvement relative to placebo and vedolizumab 300?mg q8w. Findings from sub-population analyses had similar results but were not statistically significant.
Conclusions: The NMA suggest that ustekinumab is associated with the highest likelihood of reaching response or remission at 1?year compared with placebo, adalimumab and vedolizumab. Results should be interpreted with caution because this is a novel methodology; however, the treatment sequence analysis may be the most methodologically sound analysis to derive estimates of comparative efficacy in CD in the absence of head-to-head evidence. 相似文献